Pharmaceutical - Johnson & Johnson, Rare diseases


Popular Filters

FDA backs Janssen’s Sylvant for rare disease


The US Food and Drug Administration yesterday approved Johnson & Johnson subsidiary Janssen Biotech’s…

Janssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRare diseasesRegulationsiltuximabSylvantUSA

Janssen files for simultaneous US and EU approval for Castleman disease drug


Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), yesterday…

EuropeJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRare diseasesRegulationsiltuximab

Scottish regulator backs restricted NHS use of Janssen's Zytiga; negative on BioMarin's Firdapse


The Scottish Medicines Consortium (SMC) announced yesterday that it has accepted Johnson & Johnson (NYSE:…

BioMarin PharmaceuticalEuropeFirdapseJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRare diseasesRegulationZytiga

CHMP positive on first gene therapy, Glybera; and more opinions


Reversing an earlier negative opinion (The Pharma Letter April 22), the European Medicines Agency's Committee…

AdcetrisBiotechnologyCelgeneDacogenEuropeGlyberaIstodaxJanssen-CilagJohnson & JohnsonOncologyPfizerPharmaceuticalRare diseasesRegulationTakeda PharmaceuticalsuniQureXalkori

Back to top